Latest news with #Reddy'sLaboratories
Time of India
11-06-2025
- Time of India
8 held for Semaglutide theft from Dr Reddy's lab; 2 cr drug seized
Srikakulam: The JR Puram police in Srikakulam district have arrested a gang of eight individuals, including four employees of Dr Reddy's Laboratories, in connection with the theft of about 460 grams of Semaglutide (GLP-1), a patented anti-diabetic drug worth over ₹2 crore. The drug was stolen from the company's warehouse at Pydibheemavaram for sale in the black market. Those arrested include Dr Reddy's chemists Dronadulu Suresh (31), N Appala Naidu (28), and Gollapalli Kantarao (35); warehouse staffer G V Raghavendra (33); and four others with pharma backgrounds in Hyderabad: G Suresh Reddy (40), A Tirupati (32), K Balakrishna (33), and B Naveen Kumar (33). The police said Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side can be administered by subcutaneous injection or taken orally. Basically it was the patent product of Dr Reddy's Laboratories and the product was meant for export to foreign countries. Srikakulam district police chief KV Maheswara Reddy said the GLP-1 drug was produced at Dr Reddy's Lab production unit and subsequently stored in the freezer room of the FG warehouse on February 17, 2025. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Perdagangkan CFD Emas dengan Broker Tepercaya IC Markets Mendaftar Undo Staff members later discovered that the medicine had been stolen from the freezer room on February 23, 2025. The drug can be sold by only patent persons. However, the drug has high value in the black market. Based on the complaint, the police formed three teams to solve the offences. The JR Puram police inspector M Avatharam along with his team sub-inspector S Chiranjeevi and G Laxman Rao investigated the case in multiple angles to identify the culprits. The investigation revealed that Raghavendra stole the drug from the warehouse. Later, he gave it to Appal Naidu, Suresh and Kantarao for sale of the drug in the black market. The trio gave the stolen drug to Tirupati and later it was handed over to Suresh Reddy in Hyderabad for sale. Suresh Reddy had previously worked with a pharma company and he has links with some persons involved in selling of drugs in the black market. However, he also failed to trade the stolen chemical that led to disputes among the gang. When Raghavendra asked Suresh Reddy to return the drug, he cheated them by giving fake Semaglutide powder. The police nabbed all the eight persons in connection with the case and recovered around 440 gram of stolen Semaglutide powder and 460 gms of fake Semaglutide powder from them. Police said during the audit, staff observed that 3.38 kg of Palladium Acetate, valued at over 60 lakh and stored at the warehouse within the production unit of Dr Reddy's Lab, had been stolen in May this year. Palladium acetate, or palladium(II) acetate, is a chemical is a red-brown solid and is widely used as a catalyst in various organic reactions, particularly cross coupling reactions like Suzuki and Heck reactions. The police said the same gang was involved in the case and the investigation is on to recover the stolen chemical from them.
The Hindu
11-06-2025
- The Hindu
Srikakulam police arrest eight in ₹2 crore diabetic drug theft
Srikakulam police personnel on Wednesday arrested eight persons and recovered Semaglutide, an anti-diabetic medicine, valued at over ₹2 crore. District Superintendent of Police K.V. Maheswara Reddy said, 'The material was stolen from the Dr Reddy's Laboratories manufacturing site at Pydibhimavaram in Srikakulam district.' The arrested have been identified as D. Suresh, G.V. Raghavendra, N. Appala Naidu, G. Kanta Rao, G. Suresh, A. Tirupathi, K. Balakrishna, and B. Naveen Kumar. They all come from various districts in North Andhra and surrounding areas. The Semaglutide material, weighing about 3.38 kilograms, was stolen on February 23, 2025, from the facility's freezer. On receiving a complaint from the management, Mr. Maheswar Reddy formed three teams to investigate the case. The teams led by JR Puram Circle Inspector M. Avatharam and sub-inspector S. Chiranjeevi, on investigating, found that some employees in assistance with external accomplices were involved in this rare case of high-value pharmaceutical theft.
Time of India
05-06-2025
- Business
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
&w=3840&q=100)
Business Standard
05-06-2025
- Business
- Business Standard
Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda
Global biotech major Alvotech and Hyderabad-based Dr Reddy's Laboratories (DRL) have entered into a collaboration to co-develop, manufacture, and commercialise a biosimilar version of Merck's blockbuster cancer drug Keytruda (pembrolizumab), which recorded global sales of $29.5 billion in 2024. Shares of DRL rose 3 per cent on Thursday on the BSE following the announcement. Under the agreement, both parties will jointly manage development and manufacturing responsibilities, while sharing associated costs. Each company will also hold global commercialisation rights, subject to certain exceptions. Keytruda, developed by Merck & Co., is used to treat a wide range of cancers, including lung, melanoma, and head and neck cancers. With patents for Keytruda expected to expire in major markets over the next few years, competition among biosimilar developers is intensifying. The partnership is a strategic boost to Dr Reddy's oncology portfolio—a key therapeutic area for the company—and significantly expands Iceland-based Alvotech's biosimilar pipeline. The tie-up comes amid growing global demand for cost-effective biologic alternatives in cancer care, especially in immuno-oncology, where Keytruda remains a dominant therapy. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar,' said Erez Israeli, CEO of Dr Reddy's. 'Oncology has been a top focus therapy area for us, and this collaboration further enhances our capabilities.' Alvotech Chairman and CEO Róbert Wessman said the partnership would accelerate development while broadening global access to critical biologics. 'This agreement demonstrates our ability to leverage our R&D and manufacturing platform to pursue growing global markets,' he said. Alvotech, listed on Nasdaq, is focused solely on biosimilars and already has approvals for adalimumab and ustekinumab biosimilars. Its pipeline includes candidates for autoimmune, respiratory, and oncologic indications. Dr Reddy's, which has commercialised six biosimilars in India and over 30 countries, has been scaling up global biologics operations. It launched its first biosimilar in the UK—Versavo (bevacizumab)—in 2024, and pegfilgrastim in the US and Europe through partners. With this collaboration, both companies aim to play a larger role in shaping the next phase of affordable cancer care globally.
The Hindu
05-06-2025
- Business
- The Hindu
Dr. Reddy's, Alvotech to co-develop, market biosimilar of Merck's cancer drug Keytruda
Pharma major Dr. Reddy's Laboratories and Nasdaq-listed global biotech firm Alvotech will co-develop, manufacture and commercialise a biosimilar candidate to Merck's cancer drug Keytruda (pembrolizumab) for global markets. They will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs as well as the responsibilities. 'Subject to certain exceptions, each party will have the right to commercialise the product globally,' Dr. Reddy's and Alvotech said on Thursday (June 5, 2025) in a joint statement announcing the signing of a licence agreement. The collaboration will combine their proven capabilities in biosimilars thus speeding up the development process and extending global reach for the biosimilar candidate. A registered trademark of Merck Sharp & Dohme Corp, Keytruda is indicated for the treatment of numerous cancer types. In 2024, the worldwide sales of Keytruda were $29.5 billion. Oncology top focus therapy 'Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Dr. Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said 'we are pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets.'
